Claims
- 1. A method for treating hypertension in a patient which comprises administering to the patient a therapeutically effective amount of a benzimidazole of the formula I ##STR18## wherein R.sub.1 represents a tetrahydrobenzimidazolyl group, or a benzimidazolyl group optionally substituted in the phenyl nucleus by a fluorine, chlorine or bromine atom, by a C.sub.1-3 -alkyl group, by a C.sub.1-3 -alkoxy or by a trifluoromethyl group, wherein the NH group of the above-mentioned imidazole rings may additionally be substituted by a C.sub.1-6 -alkyl group or by a C.sub.3-7 -cycloalkyl group;
- R.sub.2 represents a hydrogen atom or a straight-chained or branched C.sub.1-5 -alkyl group in which a methylene group may be replaced by a sulphur atom;
- R.sub.3 represents a carboxy, 1H-tetrazolyl or 1-triphenylmethyl-tetrazolyl group, or an alkoxycarbonyl group with a total of 2 to 5 carbon atoms; and
- R.sub.4 represents a hydrogen, fluorine, chlorine or bromine atom;
- or a pharmaceutically acceptable salt thereof.
- 2. The method of claim 1 wherein, in the benzimidazole of formula I or its pharmaceutically acceptable salt,
- R.sub.1 represents a tetrahydrobenzimidazolyl group, or a benzimidazolyl group optionally substituted in the phenyl nucleus by a fluorine, chlorine or bromine atom or by a methyl, methoxy or trifluoromethyl group, wherein the NH-group of the above-mentioned imidazole rings may additionally be substituted by a C.sub.1-6 alkyl group or by a C.sub.3-6 -cycloalkyl group;
- R.sub.2 represents a hydrogen atom or a straight-chained or branched C.sub.1-4 alkyl group in which a methylene group may be replaced by sulphur atom;
- R.sub.3 represents a carboxy group, an alkoxycarbonyl group with a total of 2 to 5 carbon atoms or a 1H-tetrazolyl group; and
- R.sub.4 represents a hydrogen, fluorine, chlorine or bromine atom.
- 3. The method of claim 1 wherein, in the benzimidazole of formula I or its pharmaceutically acceptable salt, claim 1,
- R.sub.1 is in the 6-positions and represents a 1-methylbenzimidazol-2-yl group;
- R.sub.2 represents a methyl, ethyl, n-propyl or n-butyl group;
- R.sub.3 represents a carboxy or 1H-tetrazolyl group; and
- R.sub.4 represents a hydrogen atom.
- 4. A method for treating hypertension in a patient which comprises administering to the patient a therapeutically effective mount of a compound selected from the group consisting of:
- 4'-��2-n-propyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl!methyl!biphenyl-2-carboxylic acid,
- 4'-��2-n-propyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl!methyl!-2-(1H-tetrazol-5-yl)-biphenyl,
- and the pharmaceutically salts thereof.
- 5. A benzimidazole of the formula: ##STR19## wherein R.sub.1 represents a tetrahydrobenzimidazolyl group, or a benzimidazolyl group optionally substituted in the phenyl nucleus by a fluorine, chlorine or bromine atom, by a C.sub.1-3 -alkyl group, by a C.sub.1-3 -alkoxy or by a trifluoromethyl group, wherein the NH group of the above-mentioned imidazole rings may additionally be substituted by a C.sub.1-6 -alkyl group or by a C.sub.3-7 -cycloalkyl group;
- R.sub.2 represents a hydrogen atom or a straight-chained or branched C.sub.1-5 -alkyl group in which a methylene group may be replaced by a sulphur atom;
- R.sub.3 represents a carboxy, 1H-tetrazolyl or 1-triphenylmethyl-tetrazolyl group, or an alkoxycarbonyl group with a total of 2 to 5 carbon atoms; and
- R.sub.4 represents a hydrogen, fluorine, chlorine or bromine atom;
- or a pharmaceutically acceptable salt thereof.
- 6. A benzimidazole as recited in claim 5, wherein
- R.sub.1 represents a tetrahydrobenzimidazolyl group, or a benzimidazolyl group optionally substituted in the phenyl nucleus by a fluorine, chlorine or bromine atom or by a methyl, methoxy or trifluoromethyl group, wherein the NH-group of the above-mentioned imidazole rings may additionally be substituted by a C.sub.1-6 -alkyl group or by a C.sub.3-6 -cycloalkyl group;
- R.sub.2 represents a hydrogen atom or a straight-chained or branched C.sub.1-4 -alkyl group in which a methylene group may be replaced by sulphur atom;
- R.sub.3 represents a carboxy group, an alkoxycarbonyl group with a total of 2 to 5 carbon atoms or a 1H-tetrazolyl group; and
- R.sub.4 represents a hydrogen, fluorine, chlorine or bromine atom;
- or a pharmaceutically acceptable salt thereof.
- 7. A benzimidazole as recited in claim 5, wherein
- R.sub.1 is in the 6-positions and represents a 1-methylbenzimidazol-2-yl group;
- R.sub.2 represents a methyl, ethyl, n-propyl or n-butyl group;
- R.sub.3 represents a carboxy or 1H-tetrazolyl group; and
- R.sub.4 represents a hydrogen atom;
- or a pharmaceutically acceptable salt thereof.
- 8. A compound selected from the group consisting of:
- 4'-��2-n-propyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl!methyl!biphenyl-2-carboxylic acid,
- 4'-��2-n-propyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl!methyl!-2-(1H-tetrazol-5-yl)-biphenyl,
- and the pharmaceutically salts thereof.
Priority Claims (3)
Number |
Date |
Country |
Kind |
40 23 369.3 |
Jul 1990 |
DEX |
|
40 31287.9 |
Oct 1990 |
DEX |
|
41 05 324.0 |
Feb 1991 |
DEX |
|
Parent Case Info
This is a division of application Ser. No. 08/299,693, filed Sep. 1, 1994, which is a division of application Ser. No. 08/220,472, filed Mar. 30, 1994, now U.S. Pat. No. 5,385,925, which is a continuation of application of application Ser. No. 07/732,868, filed Jul. 19, 1991, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5385925 |
Narr et al. |
Jan 1995 |
|
5591762 |
Hauel et al. |
Jan 1997 |
|
Divisions (2)
|
Number |
Date |
Country |
Parent |
299693 |
Sep 1994 |
|
Parent |
220472 |
Mar 1994 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
732868 |
Jul 1991 |
|